Clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 分析表皮生长因子受体酪氨酸酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌的临床疗效及安全性。 方法 随机对照研究。抽取2022年1月至2023年1月郑州大学第一附属医院收治的98例晚期非小细胞肺癌患者作为研究对象，按随机数字表法分为对照组和观察组，每组49例。对照组予以化疗，观察组予以化疗联合EGFR-TKI治疗。比较两组临床疗效、肿瘤标志物水平[细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及鳞状细胞癌抗原(SCC)]与不良反应发生情况。 结果 治疗后，观察组患者的客观缓解率(69.39%，34/49)高于对照组(48.98%，24/49)，P<0.05。治疗后，两组CYFRA21-1、CEA、NSE及SCC水平均低于同组治疗前，且观察组各项指标低于对照组(P<0.05)；两组不良反应发生情况比较差异未见统计学意义(P>0.05)。 结论 晚期非小细胞肺癌临床治疗中应用EGFR-TKI有助于提高患者的临床疗效，下调肿瘤标志物表达，且安全性高。 Objective To analyze the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of advanced non-small cell lung cancer. Methods This study was a randomized controlled trail. A total of 98 patients with advanced non-small cell lung cancer admitted to the First Affiliated Hospital of Zhengzhou University from January 2022 to January 2023 were selected as the study subjects, and they were divided into control group and observation group by random number table method, with 49 cases in each group. The control group was treated by chemotherapy, while the observation group was treated with EGFR-TKI. The clinical efficacy, levels of tumor markers, including cytokeratin fragment (CYFRA21-1), carcinoembryonic antigen (CEA), neuronspecific enolase (NSE) and squamous cell carcinoma antigen (SCC), and incidence of adverse reactions of the two groups were compared. Results After treatment, the objective response rate of the observation group (69.39%, 34/49) was higher than that of the control group (48.98%, 24/49), P<0.05. After treatment, the levels of CYFRA21-1, CEA, NSE and SCC in both groups were lower than those before treatment, and the above indicators in the observation group were lower than those in the control group (P<0.05). There was no significance in the incidence of adverse reactions between the two groups (P>0.05). Conclusions The application of EGFR-TKI in the clinical treatment of advanced non-small cell lung cancer is conductive to improving the clinical efficacy and down-regulating the expression of tumor markers, with high safety.
Objective To analyze the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of advanced non-small cell lung cancer. Methods This study was a randomized controlled trail. A total of 98 patients with advanced non-small cell lung cancer admitted to the First Affiliated Hospital of Zhengzhou University from January 2022 to January 2023 were selected as the study subjects, and they were divided into control group and observation group by random number table method, with 49 cases in each group. The control group was treated by chemotherapy, while the observation group was treated with EGFR-TKI. The clinical efficacy, levels of tumor markers, including cytokeratin fragment (CYFRA21-1), carcinoembryonic antigen (CEA), neuronspecific enolase (NSE) and squamous cell carcinoma antigen (SCC), and incidence of adverse reactions of the two groups were compared. Results After treatment, the objective response rate of the observation group (69.39%, 34/49) was higher than that of the control group (48.98%, 24/49), P<0.05. After treatment, the levels of CYFRA21-1, CEA, NSE and SCC in both groups were lower than those before treatment, and the above indicators in the observation group were lower than those in the control group (P<0.05). There was no significance in the incidence of adverse reactions between the two groups (P>0.05). Conclusions The application of EGFR-TKI in the clinical treatment of advanced non-small cell lung cancer is conductive to improving the clinical efficacy and down-regulating the expression of tumor markers, with high safety.
万方数据
